Abstract
Background
Intrathecal baclofen (ITB) is an effective treatment for severe spasticity. In ambulatory patients with spasticity, it is possible that ITB treatment may compromise ambulatory function by unmasking underlying muscle weakness. This retrospective study is designed to determine the long–term ambulatory function in patients receiving ITB.
Methods
Thirty–six patients with severe spasticity previously screened for response to ITB were implanted with programmable pumps that allowed for continuous infusion of ITB. Patients were followed after implantation from 1 to 13 years.
Results
All 36 patients had decreased spasticity and retained ambulatory function. Three of the 36 patients eventually became paraplegic related to underlying disease progression.
Conclusion
ITB therapy may be used in selected ambulatory patients with spasticity and is not associated with loss of ambulatory function.
Similar content being viewed by others
References
Abel NA, Smith RA (1994) Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil 75:54–58
Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J (1993) Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270:2475–2477
Albright AL, Cervi A, Singletary J (1991) Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265:1418–1422
Ashworth B (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192:540–542
Blanck TJ, Sadiq SA (1996) General anesthetics and anesthesia–associated drugs. In: Rowland LP, Klein DF (eds) Current neurologic drugs. Current Medicine, Philadelphia, pp 239–308
Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206–207
Brown P (1994) Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 57:773–777
Coffey RJ, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, Herman R, Shetter AG, Levy R, Gill B, Smith R, Wilberger J, Loeser JD, Chabal C, Feler C, Robertson JT, Penn RD, Clarke A, Burchiel KJ, Leibrock LG (1993) Intrathecal baclofen for intractable spasticity of spinal origin: results of a longterm multicenter study. J Neurosurg 78:226–232
Francisco GE (2001) Intrathecal baclofen therapy for stroke–related spasticity. Top Stroke Rehabil 8:36–46
Gerszten PC, Albright AL, Barry MJ (1997) Effect on ambulation of continuous intrathecal baclofen infusion. Pediatr Neurosurg 27(1):40–44
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2003) Measuring the impact of MS on walking ability: The 12–Item MS Walking Scale (MSWS–12). Neurology 60:31–36
Horn TS, Yablon SA, Stokic DS (2005) Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. Arch Phys Med Rehabil 86(6):1127–1133
Lassman AB, Sadiq SA (1999) Management of spasticity. In: Younger DS (ed) Motor disorders. Lippincott Williams and Wilkins, Philadelphia, pp 505–514
McLean BN (1993) Intrathecal baclofen in severe spasticity. Br J Hosp Med 49:262–267
Penn RD (1992) Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 77:236–240
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sadiq, S.A., Wang, G.C. Long–term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol 253, 563–569 (2006). https://doi.org/10.1007/s00415-005-0060-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0060-4